Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 370 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: OVARY Clear all
Active, not recruiting Phase 2 Interventional Results available

Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer

NCT03348631
View directory record Official record
Conditions
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
581
States / cities
Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 1:24 PM EDT
Withdrawn No phase listed Observational

Using CPAP to Improve Menstruation in Women With Polycystic Ovarian Syndrome and Obstructive Sleep Apnea

NCT03155828
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Anovulation, Polycystic Ovarian Syndrome
Interventions
CPAP
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Phase 3 Interventional

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

NCT00057720
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
234
States / cities
Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 30, 2026, 1:24 PM EDT
Not listed Not applicable Interventional

Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

NCT01425541
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome (PCOS)
Interventions
estrace, Progesterone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 18 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 30, 2026, 1:24 PM EDT
Active, not recruiting Not applicable Interventional

Restoring Metabolic and Reproductive Health With Sleep in PCOS Study, CPAP Trial

NCT05920694
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
Continuous Positive Airway Pressure Device (CPAP), Delayed Continuous Positive Airway Pressure Device (CPAP)
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 1:24 PM EDT
Not listed Phase 1Phase 2 Interventional

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

NCT00660101
View directory record Official record
Conditions
Adenocarcinoma of the Ovary
Interventions
OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine
Biological
Lead sponsor
AVAX Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Zion, Illinois • Tulsa, Oklahoma • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 30, 2026, 1:24 PM EDT
Terminated Phase 3 Interventional Results available

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

NCT00429403
View directory record Official record
Conditions
Breast Cancer
Interventions
Goserelin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 46 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 30, 2026, 1:24 PM EDT
Terminated Phase 1 Interventional

Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome

NCT00970541
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
Cinnamon Supplementation, Placebo (wheat flour)
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 30, 2026, 1:24 PM EDT
Withdrawn No phase listed Observational

Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer

NCT00588263
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Lung Cancer, Melanoma, Non-Hodgkin's Lymphoma, Uterine Cancer, CORPUS UTERI,ENDOMETRIUM, LUNG, OVARY
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 30, 2026, 1:24 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099
View directory record Official record
Conditions
PCOS, Polycystic Ovary Syndrome
Interventions
Micronized progesterone, Placebo, Flutamide, Estradiol patch
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 30, 2026, 1:24 PM EDT
Not listed Phase 1Phase 2 Interventional

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

NCT04205227
View directory record Official record
Conditions
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
Interventions
ENB003, Pembrolizumab
Drug
Lead sponsor
ENB Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Not applicable Interventional

An Integrated Self-Management Intervention for Adolescents With Polycystic Ovary Syndrome

NCT03600337
View directory record Official record
Conditions
PCOS
Interventions
Working to Optimize Wellness in Tees with PCOS (WOW)
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
14 Years to 23 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Phase 3 Interventional

Treatment of Infertility in Women With Polycystic Ovary Syndrome

NCT00068861
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions
metformin XR, clomiphene citrate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

Dampening the Reproductive Axis With Continuous Kisspeptin

NCT05971849
View directory record Official record
Conditions
Reproductive Disorder, PCOS, Polycystic Ovary Syndrome
Interventions
kisspeptin 112-121
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance

NCT06158932
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hormone Imbalance
Interventions
Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement
Dietary Supplement
Lead sponsor
Optify
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

NCT00283816
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Pharmacogenetics of Metformin Action in PCOS

NCT00703508
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin 500 mg tablet
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

NCT01872078
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Interventions
AZD4901 (oral), Placebo to match AZD4901
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 30, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

NCT00747617
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
recombinant human chorionic gonadotropin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 30, 2026, 1:24 PM EDT
Terminated No phase listed Observational

Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose

NCT01775176
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 30, 2026, 1:24 PM EDT
Terminated Not applicable Interventional Results available

Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

NCT01607320
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Raloxifene, Clomiphene
Drug
Lead sponsor
Bruce Lessey
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 30, 2026, 1:24 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

NCT06169124
View directory record Official record
Conditions
Adult Ovarian Granulosa Cell Tumor
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Darolutamide, Exemestane, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
66
States / cities
Los Angeles, California • Newark, Delaware • Boise, Idaho + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 1:24 PM EDT
Active, not recruiting Phase 3 Interventional

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04095364
View directory record Official record
Conditions
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
883
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 30, 2026, 1:24 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 1:24 PM EDT